Moreover, clinical studies that combine RET inhibitors and EGFR TKIs with other targeted drugs are warranted for the lung adenocarcinoma patients harboring concurrent KIF5B-RET fusion gene and EGFR or KRAS mutations. The gene discussed is RET; the disease is lung adenocarcinoma.